The medical technology developer increased its total funding to over $135m in a round backed by Naver, NSG Ventures, Kakao Ventures and SoftBank Ventures Asia.
South Korea-based cancer treatment technology developer Lunit has secured $61m in funding from investors including laboratory operator NSG Biolabs, telecommunications and internet conglomerate SoftBank and internet groups Kakao and Naver.
Legend Capital, the venture capital firm formed by conglomerate Legend Holdings, also took part in the round, as did American Cancer Society’s BrightEdge fund, IMM Investment, Mirae Asset Venture Investment, Casdin Capital, Tybourne Capital Management and HealthQuest Capital.
NSG, Kakao and SoftBank were represented by subsidiaries NSG Ventures, Kakao Ventures…
